Compare Fidelity National Information Servcs Inc (FIS) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Zimmer Biomet Holdings Inc — how do they compare? Fidelity National Information Servcs Inc trades at $34.2 (market cap $17.71B), while Zimmer Biomet Holdings Inc trades at $88.98 (market cap $16.95B). The key difference: Fidelity National Information Servcs Inc and Zimmer Biomet Holdings Inc are close in size by market cap, and Fidelity National Information Servcs Inc pays the higher dividend (5.13%). Which is the better fit depends on your goals — on Pluang, investors hold Fidelity National Information Servcs Inc for 88 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| FIS | ZBH | |
|---|---|---|
Market Cap | $17.71B | $16.95B |
Volume | 9,047,825 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $68.57 | $103.98 |
52-Week Low | $32.44 | $79.58 |
Typical Hold Time | 88 Days | 89 Days |
Enterprise Value | $38.22B | $24.02B |
Dividend Yield | 5.13% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $33.82, up 1.2% today, with a bearish technical signal despite beating earnings estimates in two of the last three quarters. The stock shows attractive valuation metrics with a P/E of 5.27 and P/S of 1.46, while analyst consensus remains strongly bullish with a $47.15 price target. Recent business developments include multiple core banking platform wins and new embedded banking offerings, signaling growth momentum in financial technology services.
The outlook appears positive given FIS's improving profitability trajectory and strong analyst support, though investors should monitor debt levels and execution risks. With revenue projected to grow to $12.2B in 2026 and net income margin expanding to 27.64%, the stock offers fundamental upside potential if the company can maintain its competitive positioning in banking technology modernization.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
